Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (January 2026)
23 slides from Netramark's investor presentation, January 2026
Slide 1: Predictive Enrichment Corporate Presentation
Predictive Enrichment C O R P O R AT E P R E S E N TAT I O N CSE: AIAI OTCQB: AINMF FRA: PF0
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this presentation has been CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in this presentation prepared by NetraMark Holdings Inc. (“NetraMark” or the
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: We Optimize Response Prediction
We Optimize Response Prediction Netra is derived from Sanskrit and means “Eyes” We leverage a Sponsor’s clinical trial data readouts using our proprietary AI to identify subpopulations driving drug response, placebo response and adverse events and inform subsequent trial strategies. The NetraMark di
Slide 5: Only 12% of candidate medicines are approved by the FDA
THE PROBLEM Only 12% of candidate medicines are approved by the FDA BASIC DRUG PRE- FDA POST-APPROVAL DISCOVERY CLINICAL TRIALS RESEARCH & MONITORING RESEARCH CLINICAL REVIEW PHASE 1 PHASE 2 PHASE 3 PHASE IV From drug discovery through FDA approval, developing a new FDA medicine takes, on average, 1
Slide 6: The clinical trial market is robust, growing and large
THE MARKET The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Global Clinical Trial Support Services (in USD Billions)2 450,000 399,522 400,000 362,500 50.0 350,000 325,771 R 45.0 C AG 293,254 % 300,000 40.0 7.2 262,299 35.0 250,000 233,124 30.
Slide 7: The Team
THE TEAM George Achilleos Josh Spiegel Dr. Joseph Geraci Chief Technology Officer/Chief Chief Executive Officer President Scientific Officer and Director 25+ years of experience in finance, sales and corporate Co-Founder of NetraMark, PhD mathematician, medical Season Business Executive with 25+ yea
Slide 8: How is the pharmaceutical industry leveraging AI to increase trial success?
THE INDUSTRY’S AI APPROACH How is the pharmaceutical industry leveraging AI to increase trial success? Competitive AI application area Competitive AI application area Clinical Trial Operations Protocol Basic Drug Data Research Discovery Readout Protocol Data Readout Less competitive AI application a
Slide 9: Over 95% of trials have less than 1,000 participants
THE BLUE OCEAN OPPORTUNITY Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. Cumulative # of trials by anticipated # of participants (1999 – 2021)* # of
Slide 10: NetraMark is uniquely positioned to analyze small clinical trial data readouts
THE NETRAMARK APPROACH NetraMark is uniquely positioned to analyze small clinical trial data readouts We utilize a unique and modern mathematical AI paradigm that has the ability to discover model derived subgroups that inform enrichment for participants most likely to drive a positive trial outcome
Slide 11: The Need for Validated Predictive Enrichment
THE NEED The Need for Validated Predictive Enrichment The Problem: Most traditional subgroup hypotheses are post-hoc and not aligned with FDA expectations for predictive enrichment (pre-specification, error control, independent validation). They are generally not suitable to serve as pre-specified,
Slide 12: Enabling Validated Predictive Enrichment for Trial Sponsors
THE SOLUTION Enabling Validated Predictive Enrichment for Trial Sponsors NetraAI’s Novel Capability: Identify and validate Model-Derived Subgroups (MDS) prospectively. • How NetraAI Works: Through sub-insight learning, it discovers explainable MDS with high treatment effect and confirms their stabil
Slide 13: Introduction: System Overview
THE SYSTEM OVERVIEW Introduction: System Overview A novel AI-driven Drug Development Tool, used by sponsors, for clinical trial enrichment. Simultaneous Simultaneous Favorable Unfavorable Outcomes Outcomes Treatment Responders Exhibit: Placebo Responders Exhibit: • Variable 1 • Variable 1 • Variable
Slide 14: The NetraMark Output: Understanding the Results
RESULTS REPORT KETAMIN! iE MOA THE NETRAMARK OUTPUT Understanding the Results Clinical Trial Simulations - Subpopulation Optimization for Endpoint Response uses a unique combinatorial approach to discover subpopulations of the “best” patients within i data that are easily characterizable by a set of
Slide 15: Case Study 2: Ketamine for MDD
CASE STUDY: KETAMINE FOR MDD Case Study 2: Ketamine for MDD Phase II randomized trial of an investigational antidepressant (intravenous ketamine) versus placebo in major depressive disorder (N = 62 patients) Data collected from each patient during trial: • High-dimensional neuroimaging data • Struct
Slide 16: Commercialization Approach
COMMERCIALIZATION Commercialization Approach • Direct to sponsors • Channel partners • Research collaborations • Peer reviewed publications • FDA Engagement
Slide 17: Direct route to market momentum
DIRECT TO SPONSORS Direct route to market momentum The direct channel focuses on engaging pharmaceutical and biotech companies without intermediaries, enabling the Company to present its AI-driven trial optimization capabilities directly to decision-makers. Key Highlights: Growing Demand: Significan
Slide 18: Channel partner momentum
CHANNEL PARTNERS Channel partner momentum Worldwide Clinical Trials (“Worldwide”): • Following the execution of a master services agreement with Worldwide Clinical Trials on April 3, 2025, NetraMark completed Worldwide’s onboarding and quality assurance process in October of 2025. • As a result, Net
Slide 19: Collaboration momentum
RESEARCH COLLABORATIONS Collaboration momentum NIMH Leading U.S. academic medical center
Slide 20: Peer reviewed publications
PEER REVIEWED PUBLICATIONS Peer reviewed publications Npj Digital Medicine Nature Portfolio Publication: • On December 8, 2025, NetraMark announced that its scientific study highlighting NetraAI was accepted for publication in npj Digital Medicine, part of the Nature Portfolio. • The peer-reviewed p
Slide 21: FDA CPIM meeting
FDA ENGAGEMENT FDA CPIM meeting Regulatory Milestone - FDA Critical Path Innovation Meeting (CPIM): • Completed a Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). • The CPIM was a non-regulatory, non-binding scientific exchange during which the FDA provided f
Slide 22: Summary
SUMMARY • Proprietary and Advanced Commercial ready platform • Technology built, gone through QA validation and is commercialized • Established high profile research collaborations with centers of excellence • Developed a focused market entry strategy • Therapeutic core focus areas – CNS and Oncolog
Slide 23: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB : AI NMF FRA: PF0
NetraMark Holdings — Investor Presentation (January 2026) on 6ix